TEVA

A Comprehensive Look At Dividend Growth Stock Valuations Sector By Sector: Part 2

Posted on by Chuck Carnevale

Introduction

Finding attractively valued dividend growth stocks is getting harder and harder to do.  The overall market has been on a relentless advance for many years now, and high quality dividend paying growth stocks have been leaders.  Consequently, valuations have become extended beyond historical norms and I contend prudence.  Nevertheless, there are attractive dividend growth stocks available if you’re willing to look hard enough.

[…]

Invest In Stocks With A Margin of Safety To Reduce Risk And Enhance Returns

Posted on by Chuck Carnevale

Introduction Of all of the many sound investing principles that legendary teacher and investor Ben Graham put forward, he believed that his concept of “margin of safety” was the most important of all.  This investment lesson was so deeply ingrained into the mind of Ben Graham’s most famous student, Warren Buffett, that he created his Read more about Invest In Stocks With A Margin of Safety To Reduce Risk And Enhance Returns[…]

A True Investor’s Most Important Performance Measurement

Posted on by Chuck Carnevale

Although most people either fail to realize it, or simply refused to accept it, every stock portfolio has two separate and distinct performances.  The first, and in my opinion, the least important, is stock price movement.  If you buy a stock at $10 a share and it goes to $15 a share it’s a good Read more about A True Investor’s Most Important Performance Measurement[…]

Teva Pharmaceutical: Dividends, Earnings And Valuation Analysis

Posted on by Julie Carnevale

. . . . Teva Pharmaceutical (TEVA): A Dividend Contender with 13 Consecutive Years of Dividend Increases Since dividends are paid out of earnings, a clear perspective of a company’s historical earnings growth record is a vital component of a dividend investor’s prudent due diligence process. The following graph plots Teva Pharmaceutical’s earnings per share Read more about Teva Pharmaceutical: Dividends, Earnings And Valuation Analysis[…]

42 Dividend Contenders for Above-Average Total Return

Posted on by Julie Carnevale

With interest rates hovering near all-time lows, investors needing income are faced with very limited choices.  The traditional high yield available from bonds and other fixed income vehicles are no longer available to meet the needs of retirees needing income to live off.  Moreover, it is almost a certainty that today’s low yields are not Read more about 42 Dividend Contenders for Above-Average Total Return[…]

Dividend Champions a Rare Undervalued Opportunity

Posted on by Julie Carnevale

We believe that based on earnings, 2012 is starting out with the stock market undervalued. We believe in the long-term ownership of great businesses purchased at sound and attractive valuations. Consequently, we view the stock market as merely the store that we shop at in order to buy the businesses we want to own. Furthermore, Read more about Dividend Champions a Rare Undervalued Opportunity[…]

America’s Best Companies are Cheap – So Merry Christmas and a Prosperous New Year!

Posted on by Julie Carnevale

Let there be no confusion about the purpose and intent of this article.  It is intended to present a positive and enthusiastic defense and a reasoned support of our great country and its economic strength and promise.  There are far too many that want to criticize and denigrate our economy and the very system within Read more about America’s Best Companies are Cheap – So Merry Christmas and a Prosperous New Year![…]

8 Strong Growth Stocks Significantly Under-valued by Mr. Market

Posted on by Julie Carnevale

Positioning Statements and Principles We don’t believe in investing in the stock market.  Instead, we believe in investing in great businesses.  Therefore, we tend to focus more on how the business is performing on an operating basis than we do on stock price volatility.  In other words, we are most interested in whether or not Read more about 8 Strong Growth Stocks Significantly Under-valued by Mr. Market[…]

Teva Pharmaceutical Has It All: Value, Growth and Yield

Posted on by Julie Carnevale

Headquartered in Israel, Teva (TEVA) is the world’s largest generic drug maker, which markets over 1200 molecules in over 60 countries throughout the world. In addition to their generic portfolio, Teva also possesses a strong branded portfolio led by Copaxone, the world’s leading injectable therapy for multiple sclerosis. Teva generates high levels of cash flow, Read more about Teva Pharmaceutical Has It All: Value, Growth and Yield[…]